This
adran has no associated
Memorandwm Esboniadol
5. For regulation 8 (amendment of Schedule 1 (further provisions for classification of medicinal products)) substitute—U.K.
“8. In Schedule 1—
(a)in paragraph 1—
(i)in sub-paragraph (b), insert “ UK ” before “marketing authorisation”;
(ii)in sub-paragraphs (e)(i), (f)(i) and (g)(i), for “marketing authorisation” substitute “ UK marketing authorisation, EU marketing authorisation, Article 126a authorisation or parallel import licence ”; and
(b)in paragraph 4, for “marketing authorisation” substitute “ UK marketing authorisation, EU marketing authorisation, Article 126a authorisation, parallel import licence ”.”.
Commencement Information
I1Sch. 2 para. 5 in force at 31.12.2020 immediately before IP completion day, see reg. 1